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in children aged 12, 18 months and at school entry (aged
6-7 years) in Saudi Arabia, in order to support inclusion of
Hepatitis A and varicella vaccinations into national sched-
ules.
Methods: Cross-sectional, prospective, multi-centric
study conducted in 70 primary healthcare centres (PHCs)
selected randomly, across ﬁve provinces covering different
regions of Saudi Arabia. Multi-stage sampling technique was
used and all children were selected randomly. After consent
was obtained, questionnaires were given to parents to col-
lect demographic data and medical history. A blood sample
was collected from all enrolled children and tested for anti-
hepatitis A virus (HAV) and anti-varicella zoster virus (VZV)
antibodies.
Results: 5006 children (845 aged 12 months, 843 aged
18 months and 3318 aged 6—7 years) were recruited and
51.4% of them were males. Overall, 13.9% and 30% of
the subjects were seropositive for anti-HAV and anti-VZV
antibodies, respectively. Seropositivity rates in increasing
order of survey age groups was: 13.5%, 8.4% and 15.4%
for anti-HAV; 6.9%, 8.8% and 41.2% for anti-VZV. A signif-
icant difference (P < 0.05 Fisher’s exact two-sided test) in
anti-HAV seropositivity rates was observed between the 12
and 18 months age groups (13.5% and 8.4% in the 12 and
18 months age groups, respectively). Signiﬁcant differences
were observed in anti-HAV and anti-VZV seroprevalence
with respect to urban and rural areas in two out of ﬁve
provinces.
Conclusion: Data from this ﬁrst national survey indicates
that a large population of children in the age groups included
in the survey are at risk of future HAV and VZV infections,
and supports the recent inclusion of HAV (2 doses at 18 and
24 months of age) and VZV vaccines (2 doses at 12 months
of age and pre-school) as part of Saudi Arabian Extended
Program of Immunisation.
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Inﬂuenza is an acute viral respiratory disease and usu-
ally develops mild symptoms. But sometimes it causes
severe complications which may lead to hospitalizations and
deaths. The disease burden of inﬂuenza is poorly exam-
ined in developing countries in Asia including Mongolia.
Mongolia is locates in the mountainous plateau of East
Central Asia with 2.5million population. Ulaanbaatar is
the capital city of Mongolia and almost one third of the
national population lives there. The national inﬂuenza sen-
tinel surveillance indicates a clear seasonality for morbidity
of inﬂuenza-like illness (ILI). To examine a disease burden
of inﬂuenza, we tried to estimate excess deaths among
all cause deaths in this study. Monthly all cause deaths in
Ulaanbaatar were obtained from January, 2004 to December,
2007 from the national medical statistics database. The data
of population size was also obtained from national census
2000. We applied the Serﬂing model to estimate a base-
line threshold with deﬁning as seasonal inﬂuenza occurred
between November and April. Excess mortality number were
estimated the difference between observed number and
baseline threshold. It was observed some tendency for win-
ter seasonality among all cause deaths for Mongolia as a
whole, but not in Ulaanbaatar though this tendency was
not statistically signiﬁcant. This may be explained by sev-
eral reasons. First, the validity of data source may affect
this result. Second, other social factors such as improving
infant health and nutrition may partly affect this result.
In conclusion, no seasonal excess mortality was observed
from this preliminary study despite of clear seasonal pat-
tern for ILI morbidity in Mongolia. Further study is necessary
to estimate the precise inﬂuenza disease burden in Mongo-
lia.
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Group A rotavirus (RV) is the most common cause of acute
gastroenteritis in children ≤5 years of age worldwide, caus-
ing approximately 600,000 deaths annually. Rotaviruses are
characterized by their two surface proteins, VP4 (P) and VP7
(G). Five common P and G type combinations are common
worldwide: G1P1A[8], G2P1B[4], G3P1A[8], G4P1A[8], and
G9P1A[8]. Other P/G combinations are currently regionally
important, including G5P1A[8] in Brazil, G8P2A[6] in Malawi,
and G9P2A[6] in India. To study the molecular diversity of
RV strains in several countries in the American continent,
∼1200 stool samples from children with gastroenteritis were
collected from 2004 to 2008. RT-PCR and sequence anal-
ysis for VP7 and VP4 were used to determine the P and
G types of approximately 1000 RV-positive stool samples.
During the 2006—2007 RV season in the Philadelphia area,
21% (65/305) of the RV-positive symptomatic cases were
G2P2A[6] strains, while 5% (14/305) of the circulating symp-
tomatic RV cases were caused by the classical G2P1B[4]
combination. Sequence analysis showed a 98% amino acid
identity among all 79 G2 VP7 sequences over the 102 peptide
region sequenced. During the current 2007—2008 RV season
in Latin America, 6.3% (5/79) of the RV-positive symptomatic
cases were identiﬁed as G4P2A[6]. G4P2A[6] and G2P2A[6]
RV strains are increasingly being reported in symptomatic RV
cases around the globe. Taken together, our ﬁndings indicate
that P2A[6], which was previously thought to be associated
with asymptomatic RV strains, is beginning to be identiﬁed
as an important genotype associated with symptomatic RV
strains in the Americas. Further epidemiological and molec-
ular studies will determine if RV strains associated with
the P2A[6] VP4 type are clinically relevant, and whether
their increased prevalence would impact the efﬁcacy of two
